Clinical Trial News and Research

RSS

Vitamin D2 supplements may help prevent falls among high-risk older women

Vitamin D2 supplements appear to reduce the risk of falls among women with a history of falling and low blood vitamin D levels living in sunny climates, especially during the winter, according to a report in the January 14 issue of Archives of Internal Medicine.

16 Jan 2008

New phase of additional funds to support clinical trials methods in UK

The Medical Research Council has launched a new initiative to establish regional hubs of excellence to develop better methods for conducting clinical trials.

15 Jan 2008

New multi-drug resistant microbe bad news for gay men

Sexually active gay men are many times more likely than others to acquire a new, highly antibiotic-resistant strain of the so-called MRSA bacteria widely know as the "superbug," a UCSF-led study shows.

15 Jan 2008

Improving informed consent

New ways to make sure people are adequately informed about the risks and benefits of taking part in a clinical trial can be field-tested for effectiveness as vigorously as new medical treatments themselves, a study led by a Johns Hopkins bioethicist suggests.

15 Jan 2008

Most people with diabetes would benefit from statins

Most people who have diabetes would benefit from statin therapy, even if they have not yet developed symptoms or signs of vascular disease such as heart disease and stroke.

14 Jan 2008

Cranberries combat urinary tract infections

Cranberry juice, long dissed as a mere folk remedy for relieving urinary tract infections in women, is finally getting some respect.

11 Jan 2008

Trichloroethylene exposure linked to Parkinsonism

Industrial workers who worked with trichloroethylene (TCE) may face a greater risk for parkinsonism, a study by a team of University of Kentucky researchers shows.

10 Jan 2008

Trius Therapeutics starts U.S. phase I trial for Oxazolidinone antibacterial drug

Trius Therapeutics, Inc. has announced that it initiated its first Phase 1 clinical trial of TR-701, an antibacterial drug candidate intended for treatment of patients with serious Gram-positive bacterial infections, including those caused by MRSA and other drug-resistant strains.

9 Jan 2008

New method for presenting clinical trial survival data

Researchers have developed a new method for presenting clinical trial survival data that includes data from all trial participants unlike the standard method, according to a commentary published online January 8 in the Journal of the National Cancer Institute.

9 Jan 2008

Taranabant shows promise for weight loss in obese people

The first clinical studies of an experimental drug have revealed that obese people who take it for 12 weeks lose weight, even at very low doses.

9 Jan 2008

Docetaxel given after doxorubicin reduces recurrence

Adding the drug docetaxel to anthracycline-based chemotherapy slightly improved disease-free survival in breast cancer patients, according to a randomized clinical trial published online January 8 in the Journal of the National Cancer Institute.

9 Jan 2008

Trichloroethylene chemical - widely used in industry - is a risk factor for parkinsonism

Parkinson's disease, the most common neurodegenerative movement disorder caused by aging, can also be caused by pesticides and other neurotoxins.

8 Jan 2008

Oncolytics Biotech announces new reovirus, cyclophosphamide research

Oncolytics Biotech Inc. has reported that a research group led by Dr. Richard Vile of the Mayo Clinic College of Medicine in Rochester, Minnesota, published the results of its work testing the antitumor efficacy and safety of various combinations of reovirus and cyclophosphamide in vivo.

8 Jan 2008

Daiichi Sankyo, Lilly submit NDA for investigational antiplatelet drug, Prasugrelin U.S.

Daiichi Sankyo Company, Limited and Eli Lilly and Company have announced that on Wednesday, Dec. 26, 2007, they submitted a New Drug Application (NDA) for prasugrel to the U.S. Food and Drug Administration (FDA).

7 Jan 2008

Novel anti-tumor compound

Researchers at Emory University have developed a novel anti-tumor compound that represents a distinct strategy: targeting one of the most important "intercept points" for cancer cells.

4 Jan 2008

FDA clears first rapid blood test for MRSA

The U.S. Food and Drug Administration (FDA) has announced it has cleared for marketing the first rapid blood test for the drug-resistant staph bacterium known as MRSA (methicillin-resistant Staphylococcus aureus), which can cause potentially deadly infections.

3 Jan 2008